These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 33919434)

  • 1. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease.
    Iznardo H; Puig L
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives.
    Iznardo H; Puig L
    Expert Rev Clin Immunol; 2021 Feb; 17(2):187-199. PubMed ID: 33538202
    [No Abstract]   [Full Text] [Related]  

  • 3. IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications.
    Iznardo H; Puig L
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors.
    Maçães CO; Lé AM; Torres T
    J Dermatolog Treat; 2022 Nov; 33(7):2911-2918. PubMed ID: 35695278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spesolimab: A Novel Treatment for Pustular Psoriasis.
    Ratnarajah K; Jfri A; Litvinov IV; Netchiporouk E
    J Cutan Med Surg; 2020; 24(2):199-200. PubMed ID: 32208020
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of IL 23 in the treatment of psoriasis.
    Puig L
    Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis.
    Su Z; Paulsboe S; Wetter J; Salte K; Kannan A; Mathew S; Horowitz A; Gerstein C; Namovic M; Todorović V; Seagal J; Edelmayer RM; Viner M; Rinaldi L; Zhou L; Leys L; Huang S; Wang L; Sadhukhan R; Honore P; McGaraughty S; Scott VE
    Exp Dermatol; 2019 Feb; 28(2):113-120. PubMed ID: 30417427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New and Emerging Treatments for Generalized Pustular Psoriasis: Focus on IL-36 Receptor Inhibitors.
    Vilaça J; Yilmaz O; Torres T
    Pharmaceutics; 2024 Jul; 16(7):. PubMed ID: 39065604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoinflammatory process in the pathogenesis of generalized pustular psoriasis and perspectives of its targeted therapy.
    Javor J; Buc M; Bucová M
    Epidemiol Mikrobiol Imunol; 2021; 70(3):199-207. PubMed ID: 34641694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
    Chiricozzi A
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis.
    Furue K; Yamamura K; Tsuji G; Mitoma C; Uchi H; Nakahara T; Kido-Nakahara M; Kadono T; Furue M
    Acta Derm Venereol; 2018 Jan; 98(1):5-13. PubMed ID: 28967976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis.
    Burden AD
    Expert Rev Clin Immunol; 2023 May; 19(5):473-481. PubMed ID: 36960829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.
    Elewski BE; Lebwohl MG; Anadkat MJ; Barker J; Ghoreschi K; Imafuku S; Mrowietz U; Li L; Quaresma M; Thoma C; Bachelez H
    J Am Acad Dermatol; 2023 Jul; 89(1):36-44. PubMed ID: 36870370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases.
    Walsh PT; Fallon PG
    Ann N Y Acad Sci; 2018 Apr; 1417(1):23-34. PubMed ID: 27783881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.
    Warren RB; Reich A; Kaszuba A; Placek W; Griffiths CEM; Zhou J; Randazzo B; Lizzul P; Gudjonsson JE
    Br J Dermatol; 2023 Jul; 189(2):161-169. PubMed ID: 37120722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
    Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
    Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risankizumab for the treatment of moderate to severe psoriasis.
    Chiricozzi A; Antonioli L; Panduri S; Fornai M; Romanelli M; Blandizzi C
    Expert Opin Biol Ther; 2019 Jan; 19(1):1-8. PubMed ID: 30462554
    [No Abstract]   [Full Text] [Related]  

  • 19. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Puig L
    Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.
    Baum P; Visvanathan S; Garcet S; Roy J; Schmid R; Bossert S; Lang B; Bachelez H; Bissonnette R; Thoma C; Krueger JG
    J Allergy Clin Immunol; 2022 Apr; 149(4):1402-1412. PubMed ID: 34678325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.